Physician profile
Daniel J Lee
NPI 1588751135
$594.88
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $508 · 2020: $22.90 · 2021: $39.02 · 2022: $24.88.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acessa Health INC. | $226.32 | 2019 | |
| Abbvie INC. | $84.86 | 2019 | |
| Roche Diagnostics Corporation | $47.48 | 2019 | |
| Therapeuticsmd, INC. | $38.15 | 2019 | |
| Amgen INC. | $33.57 | 2019 | |
| Abbott Laboratories | $24.88 | 2022 | |
| Daiichi Sankyo INC. | $22.90 | 2020 | |
| Teleflex LLC | $22.89 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $20.43 | 2019 | |
| Boston Scientific Corporation | $17.48 | 2019 | |
| Merck Sharp & Dohme LLC | $16.50 | 2019 | |
| Organon LLC | $16.13 | 2021 | |
| Coopersurgical, INC. | $12.23 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $11.06 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.